<DOC>
	<DOCNO>NCT02567435</DOCNO>
	<brief_summary>This randomized phase III trial study well combination chemotherapy ( vincristine sulfate , dactinomycin , cyclophosphamide alternate vincristine sulfate irinotecan hydrochloride ) work compare combination chemotherapy plus temsirolimus treating patient rhabdomyosarcoma ( cancer form soft tissue , muscle ) , intermediate chance come back treatment ( intermediate risk ) . Drugs use chemotherapy work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Combination chemotherapy temsirolimus may stop growth tumor cell block enzymes need cell growth . It yet know whether combination chemotherapy combination chemotherapy plus temsirolimus effective treating patient intermediate-risk rhabdomyosarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Temsirolimus Treating Patients With Intermediate Risk Rhabdomyosarcoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare event-free survival ( EFS ) patient intermediate-risk ( IR ) rhabdomyosarcoma ( RMS ) treat surgery , radiotherapy , vincristine ( vincristine sulfate ) , dactinomycin , cyclophosphamide ( VAC ) alternate vincristine irinotecan ( irinotecan hydrochloride ) ( VI ) ( VAC/VI ) patient treat surgery , radiotherapy VAC/VI plus temsirolimus ( TORI ) . SECONDARY OBJECTIVES : I . To compare overall survival ( OS ) patient IR RMS treat surgery , radiotherapy , VAC alternate VI patient treat surgery , radiotherapy VAC/VI plus TORI . TERTIARY OBJECTIVES : I . To compare outcome patient base forkhead box O1 protein ( FOXO1 ) fusion gene partner , evaluate pair box ( PAX ) 3 vs PAX7 patient find FOXO1 fusion positive . II . To compare outcome patient base [ F18 ] -fluorodeoxy-D-glucose-positron emission tomography ( FDG-PET ) response week 9 ( positive negative ) , assess Deauville criterion ( 5-point ) . OUTLINE : FEASIBILITY PHASE : ( &lt; 21 year old ) : This dose-escalation study temsirolimus . Patients receive vincristine sulfate intravenously ( IV ) 1 minute day 1 week 1-13 , 16 , 17 , 19 , 20 , 22-26 , 28 , 31-34 , 37 , 38 , 40 , dactinomycin IV 1-5 minute day 1 week 1 , 7 , 13 , 22 , 28 , 34 , 40 , cyclophosphamide IV 60 minute day 1 week 1 , 7 , 13 , 22 , 28 , 34 , 40 , irinotecan hydrochloride IV 90 minute day 1-5 week 4 , 10 , 16 , 19 , 25 , 31 , 37 , temsirolimus IV 30-60 minute day 1 , 8 , 15 . Patients also undergo radiation therapy ( RT ) begin week 13 6 week . Courses temsirolimus repeat every 21 day 12 week absence disease progression unacceptable toxicity . EFFICACY PHASE : Patients randomize Regimen A B . Patients disease ARMS FOXO1 fusion negative ( stage I , group I/II , stage 1 , group III [ orbit ] stage II , group I/II ) assign Regimen C. REGIMEN A ( VAC/VI ) : Patients receive vincristine sulfate IV 1 minute day 1 week 1-13 , 16 , 17 , 19 , 20 , 22-26 , 28 , 31-34 , 37 , 38 , 40 , dactinomycin IV 1-5 minute day 1 week 1 , 7 , 13 , 22 , 28 , 34 , 40 , cyclophosphamide IV 60 minute day 1 week 1 , 7 , 13 , 22 , 28 , 34 , 40 , irinotecan hydrochloride IV 90 minute day 1-5 week 4 , 10 , 16 , 19 , 25 , 31 , 37 . Patients also undergo RT begin week 13 6 week . Treatment continue absence disease progression unacceptable toxicity . REGIMEN B ( VAC/VI TORI ) : Patients receive vincristine sulfate IV 1 minute day 1 week 1-13 , 16 , 17 , 19 , 20 , 22-26 , 28 , 31-34 , 37 , 38 , 40 , dactinomycin IV 1-5 minute day 1 week 1 , 7 , 13 , 22 , 28 , 34 , 40 , cyclophosphamide IV 60 minute day 1 week 1 , 7 , 13 , 22 , 28 , 34 , 40 , irinotecan hydrochloride IV 90 minute day 1-5 week 4 , 10 , 16 , 19 , 25 , 31 , 37 temsirolimus IV 30-60 minute day 1 week 1-12 21-42 . Patients also undergo RT Regimen I . Treatment continue absence disease progression unacceptable toxicity . REGIMEN C ( FOXO1 FUSION NEGATIVE ) : Patients receive VAC/VA RT . After completion study treatment , patient follow every 3 month 1 year , every 4 month 2 year , every 6 month 1 year , annually 10 year .</detailed_description>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma , Embryonal</mesh_term>
	<mesh_term>Rhabdomyosarcoma , Alveolar</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<criteria>Feasibility Phase : Patients must &lt; 21 year age time enrollment Efficacy Phase : Patients must = &lt; 40 year age time enrollment Patients newly diagnose RMS subtype , except adulttype pleomorphic , base upon institutional histopathologic classification , eligible enroll study base upon stage , group , age , RMS type include embryonal rhabdomyosarcoma ( ERMS ) include classified 1995 International Classification Rhabdomyosarcoma ( ICR ) ERMS ( classic , spindle cell , botryoid variant ) , reclassified 2013 World Health Organization ( WHO ) classification ERMS ( classic , dense botryoid variant ) spindle cell/sclerosing RMS ( encompass historical spindle cell ERMS variant newly recognize sclerosing RMS variant ) ; classification alveolar rhabdomyosarcoma ( ARMS ) 2013 WHO classification ICR include classic solid variant ERMS Stage 1 , group III ( nonorbit ) Stage 3 , group I/II Stage 2/3 , group III Stage 4 , group IV , &lt; 10 year old ARMS : Stages 13 , group IIII Specimen Submission : Patients must sufficient tissue available require biology study Lansky performance status score &gt; = 50 patient = &lt; 16 year age ; Karnofsky performance status score &gt; = 50 patient &gt; 16 year age Peripheral absolute neutrophil count ( ANC ) &gt; = 750/uL Platelet count &gt; = 75,000/uL Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; = 70 mL/min/1.73 m^2 serum creatinine base age/gender follow : 1 month &lt; 6 month old : 0.4 mg/dl ( male ) , 0.4 mg/dl ( female ) 6 month &lt; 1 year old : 0.5 mg/dl ( male ) , 0.5 mg/dl ( female ) 1 &lt; 2 year old : 0.6 mg/dl ( male ) , 0.6 mg/dl ( female ) 2 &lt; 6 year old : 0.8 mg/dl ( male ) , 0.8 mg/dl ( female ) 6 &lt; 10 year old : 1 mg/dl ( male ) , 1 mg/dl ( female ) 10 &lt; 13 year old : 1.2 mg/dl ( male ) , 1.2 mg/dl ( female ) 13 &lt; 16 year old : 1.5 mg/dl ( male ) , 1.4 mg/dl ( female ) &gt; = 16 year old : 1.7 mg/dl ( male ) , 1.4 mg/dl ( female ) Patients elevate serum creatinine due obstructive hydronephrosis secondary tumor still eligible ; however , patient urinary tract obstruction tumor must unimpeded urinary flow establish via diversion ( ie . percutaneous nephrostomies ureteric stent ) urinary tract Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) age All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet FOXO1 Fusion Status : All patient undergo institutional pathology review FOXO1 fusion determination ; FOXO1 status result must available week 3 ( day 21 ) therapy ; patient eligible remain protocol therapy base upon stage , group , age : FOXO1 fusion negative : Stage 1 , group III ( nonorbit ) Stage 3 , group I/II Stage 2/3 , group III Stage 4 , group IV , &lt; 10 year old FOXO1 fusion positive : Stage 13 , group IIII Note : FOXO1 fusion status must perform local institution Patients institutional histologic classification ARMS FOXO1 fusion negative following stage group remain study receive VAC/VA therapy Regimen C instead previously assign treatment regimen ; patient consent require transfer Regimen C Stage 1 , group I/II Stage 1 , group III ( orbit ) Stage 2 , group I/II Patients previously receive TORI , another mTOR inhibitor , investigational agent Patients receive chemotherapy ( exclude steroid ) and/or radiation therapy prior enrollment Patients uncontrolled hyperglycemia Patients uncontrolled hyperlipidemia Sexually active patient reproductive potential agree use effective contraceptive method duration study participation least 3 month treatment complete sexually active reproductive potential Female patient pregnant eligible ; Note : pregnancy test require female patient childbearing potential prior study entry Lactating female plan breastfeed infant eligible</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>